

Trasyol Settlement with Bayer Pharmaceutical for \$9.475 million

Babbitt, Johnson, Osborne, & Leclainche was appointed to the Plaintiffs Steering Committee for the Trasyol Multidistrict Litigation in West Palm Beach, Fl. Trasyol, a drug used to limit bleeding during heart surgery, was marketed by Bayer Pharmaceuticals as a safe and effective medication. In 2006, after the drug had been on the market for nearly twelve years and was used in approximately one-third of heart operations in America, a study performed by Doctor Dennis Mangano indicated that the use of Trasyol had serious side effects. These included kidney damage, kidney failure, and even death. Bayer took little notice of Dr. Mangano's findings and continued to sell the drug for another two years, until, the FDA urged that Trasyol be withdrawn from the market in November 2007. In this two year period, Trasyol was found to be the cause of approximately 22,000 deaths and numerous catastrophic injuries. Through aggressive advocacy, and most importantly, unparalleled dedication and support for its clients, the law firm of Babbitt, Johnson, Osborne, & Leclainche is pleased to announce a settlement of \$9.475 million with Bayer to resolve its Trasyol claims